Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)

NCT04060199 is registered in ClinicalTrials.gov with NS Pharma, Inc. as lead sponsor.

NCT NCT04060199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04060199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
NS Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 14, 2020
Completion date
October 19, 2023
Enrollment
77 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy